Mianseryna a depresja, lęk, bezsenność Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2022
Słowa kluczowe:
bezsenność, depresja, mianseryna, zaburzenia lękowe, zaburzenia nastroju, leczenie ambulatoryjne
##plugins.themes.bootstrap3.article.main##
Abstrakt
Mianseryna jest lekiem stosowanym od wielu lat w zmniejszaniu nasilenia objawów depresji, takich jak: obniżenie nastroju, lęk, bezsenność. Poważnie upośledzają one funkcjonowanie chorego, a nieleczone mogą doprowadzić do nawrotu depresji. Korzystną cechą leku jest niski potencjał do wchodzenia w niekorzystne interakcje z innymi lekami. Z tego powodu jego podawanie może być szczególnie uzasadnione u osób starszych i obciążonych chorobami współistniejącymi.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Gładka , A., & Rymaszewska , J. (2022). Mianseryna a depresja, lęk, bezsenność . Medycyna Faktów , 15(1(54), 109-113. https://doi.org/10.24292/01.MF.0122.15
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Dean J, Keshavan M. The neurobiology of depression: An integrated view. Asian J Psychiatr. 2017; 27: 101-11. http://doi.org/10.1016/j.ajp.2017.01.025.
2. Asarnow LD, Manber R. Cognitive Behavioral Therapy for Insomnia in Depression. Sleep Med Clin. 2019; 14(2): 177-84. http://doi.org/10.1016/j.jsmc.2019.01.009.
3. Protti M, Mandrioli R, Marasca C et al. New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. Med Res Rev. 2020; 40(5): 1794-832.
4. Sacre S, Jaxa-Chamiec A, Low CMR et al. Structural Modification of the Antidepressant Mianserin Suggests That Its Anti-inflammatory Activity May Be Independent of 5-Hydroxytryptamine Receptors. Front Immunol. 2019; 10: 1167. http://doi.org/10.3389/fimmu.2019.01167.
5. Charakterystyka produktu leczniczego Deprexolet.
6. Bazire S. Przewodnik leków psychotropowych 2018. Lloyd-Reinhold Publications Limited. Stephen Bazire 2020.
7. Pinder RM, Fink M. Mianserin. Mod Probl Pharmacopsychiatry. 1982; 18: 70-101. http://doi.org/10.1159/000406237.
8. Kennedy SH, Lam RW, McIntyre RS et al; Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016. Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. The Canadian Journal of Psychiatry.
9. Gabriel FC, de Melo DO, Fráguas R et al. Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations. PLoS One. 2020; 15(4): e0231700. http://doi.org/10.1371/journal.pone.0231700.
10. Riblet N, Larson R, Watts BV et al. Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. General Hospital Psychiatry. 2014; 36(5): 466-73. http://doi.org/10.1016/j.genhosppsych.2014.05.010.
11. Sobańska A, Wichniak A, Wierzbicka A et al. Mianseryna w leczeniu bezsenności pierwotnej. Sen. 2006; 6(2): 58-63.
12. Palomäki H, Berg A, Meririnne E et al. Complaints of poststroke insomnia and its treatment with mianserin. Cerebrovasc Dis. 2003; 15(1-2): 56-62. http://doi.org/10.1159/000067127.
13. Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol. 2014; 17(2): 343-54. http://doi.org/10.1017/S1461145713000667.
14. Poyurovsky M, Koren D, Gonopolsky I et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol. 2003; 13: 123-8. http://doi.org/10.1016/S0924-977X(02)00155-4.
15. Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm. 2011; 33(3): 484-92. http://doi.org/10.1007/s11096-011-9507-0.
2. Asarnow LD, Manber R. Cognitive Behavioral Therapy for Insomnia in Depression. Sleep Med Clin. 2019; 14(2): 177-84. http://doi.org/10.1016/j.jsmc.2019.01.009.
3. Protti M, Mandrioli R, Marasca C et al. New-generation, non-SSRI antidepressants: Drug-drug interactions and therapeutic drug monitoring. Part 2: NaSSAs, NRIs, SNDRIs, MASSAs, NDRIs, and others. Med Res Rev. 2020; 40(5): 1794-832.
4. Sacre S, Jaxa-Chamiec A, Low CMR et al. Structural Modification of the Antidepressant Mianserin Suggests That Its Anti-inflammatory Activity May Be Independent of 5-Hydroxytryptamine Receptors. Front Immunol. 2019; 10: 1167. http://doi.org/10.3389/fimmu.2019.01167.
5. Charakterystyka produktu leczniczego Deprexolet.
6. Bazire S. Przewodnik leków psychotropowych 2018. Lloyd-Reinhold Publications Limited. Stephen Bazire 2020.
7. Pinder RM, Fink M. Mianserin. Mod Probl Pharmacopsychiatry. 1982; 18: 70-101. http://doi.org/10.1159/000406237.
8. Kennedy SH, Lam RW, McIntyre RS et al; Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016. Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments. The Canadian Journal of Psychiatry.
9. Gabriel FC, de Melo DO, Fráguas R et al. Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations. PLoS One. 2020; 15(4): e0231700. http://doi.org/10.1371/journal.pone.0231700.
10. Riblet N, Larson R, Watts BV et al. Reevaluating the role of antidepressants in cancer-related depression: a systematic review and meta-analysis. General Hospital Psychiatry. 2014; 36(5): 466-73. http://doi.org/10.1016/j.genhosppsych.2014.05.010.
11. Sobańska A, Wichniak A, Wierzbicka A et al. Mianseryna w leczeniu bezsenności pierwotnej. Sen. 2006; 6(2): 58-63.
12. Palomäki H, Berg A, Meririnne E et al. Complaints of poststroke insomnia and its treatment with mianserin. Cerebrovasc Dis. 2003; 15(1-2): 56-62. http://doi.org/10.1159/000067127.
13. Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol. 2014; 17(2): 343-54. http://doi.org/10.1017/S1461145713000667.
14. Poyurovsky M, Koren D, Gonopolsky I et al. Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. Eur Neuropsychopharmacol. 2003; 13: 123-8. http://doi.org/10.1016/S0924-977X(02)00155-4.
15. Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm. 2011; 33(3): 484-92. http://doi.org/10.1007/s11096-011-9507-0.